Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Sign Up to like & getrecommendations! Published in 2019 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-019-0561-x
Abstract: PurposeUsing data from the 2-year, randomized, double-dummy VERO trial, we examined the changes in 25-hydroxy-vitamin D (25[OH]D) concentrations over time, and whether the fracture risk reduction of teriparatide versus risedronate varies by baseline 25(OH)D sufficiency… read more here.
Keywords: risk; trial; teriparatide versus; risedronate ... See more keywords